Chokshi & Queen Wealth Advisors Inc Buys 90 Shares of Eli Lilly and Company $LLY

Chokshi & Queen Wealth Advisors Inc increased its stake in Eli Lilly and Company (NYSE:LLY) by 9.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,036 shares of the company’s stock after buying an additional 90 shares during the quarter. Eli Lilly and Company comprises approximately 0.5% of Chokshi & Queen Wealth Advisors Inc’s holdings, making the stock its 25th largest holding. Chokshi & Queen Wealth Advisors Inc’s holdings in Eli Lilly and Company were worth $807,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. WestEnd Advisors LLC increased its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter worth $27,000. Blume Capital Management Inc. increased its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the period. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the period. Finally, IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth $35,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 over the last three months. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $799.85 on Wednesday. The firm has a market cap of $757.03 billion, a P/E ratio of 52.28, a P/E/G ratio of 1.16 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The stock’s fifty day moving average price is $759.77 and its 200-day moving average price is $766.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Guggenheim reiterated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. Finally, The Goldman Sachs Group increased their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.